These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 1826)

  • 1. Proceedings: Butaclamol in the treatment of schizophrenia--a comparison of two treatment methods.
    Imaz F; Ban TA; Lehmann HE
    Psychopharmacol Bull; 1976 Jan; 12(1):31-4. PubMed ID: 1826
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of butaclamol in chronic schizophrenic patients.
    Clark ML; Paredes A; Costiloe JP; Wood F
    J Clin Pharmacol; 1977; 17(8-9):529-36. PubMed ID: 19510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Butaclamol hydrochloride in newly admitted schizophrenics.
    Hollister LE; Davis KL; Berger PA
    Psychopharmacol Commun; 1975; 1(5):493-500. PubMed ID: 778939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protrptyline in the treatment of chronic schizophrenic patients.
    Arbitman R; Yurtcu A; Lehmann HE; Sterlin C; Ban TA; Jarrold L
    Curr Ther Res Clin Exp; 1970 Mar; 12(3):131-5. PubMed ID: 4985491
    [No Abstract]   [Full Text] [Related]  

  • 5. [Butaclamol in acute schizophrenia].
    Gallart Capdevila JM
    Arch Neurobiol (Madr); 1975; 38(6):545-86. PubMed ID: 1225244
    [No Abstract]   [Full Text] [Related]  

  • 6. Antipsychotic effects of AL 1965.
    Sathananthan G; Mir P; Gershon S
    Curr Ther Res Clin Exp; 1976 May; 19(5):516-9. PubMed ID: 7435
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pilot study on oxaflumazine, a new piperazinated phenothiazine].
    Villeneuve A; Dogan K; Lachance R; Drolet A
    Int J Clin Pharmacol; 1972 Aug; 6(3):246-55. PubMed ID: 4405378
    [No Abstract]   [Full Text] [Related]  

  • 8. [Report on an open investigation on bromperidol, a neuroleptic of the butyrophenone series].
    Fleischhauer J
    Int Pharmacopsychiatry; 1978; 13 Suppl 1():30-7. PubMed ID: 35476
    [No Abstract]   [Full Text] [Related]  

  • 9. Piperacetazine in ambulatory chronic schizophrenic patients.
    Rada RT; Donlon PT
    Curr Ther Res Clin Exp; 1974 Feb; 16(2):124-9. PubMed ID: 4156665
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical effectiveness of piperacetazine injection in schizophrenic patients: a controlled study.
    Kulkarni AS
    Adv Biochem Psychopharmacol; 1974; 9(0):691-9. PubMed ID: 4151770
    [No Abstract]   [Full Text] [Related]  

  • 11. A comparative study with pipothiazine palmitate and fluphenazine enanthate in the treatment of schizophrenic patients.
    Jain RC; Ananth JV; Lehmann HE; Ban TA
    Curr Ther Res Clin Exp; 1975 Oct; 18(4):585-9. PubMed ID: 241609
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of rubidium in schizophrenia.
    Chouinard G; Annable L
    Commun Psychopharmacol; 1977; 1(4):373-83. PubMed ID: 28202
    [No Abstract]   [Full Text] [Related]  

  • 13. Factors which can make patients difficult to treat.
    Kane JM
    Br J Psychiatry Suppl; 1996 Dec; (31):10-4. PubMed ID: 8968650
    [No Abstract]   [Full Text] [Related]  

  • 14. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
    Kopala LC; Fredrikson D; Good KP; Honer WG
    Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777
    [No Abstract]   [Full Text] [Related]  

  • 15. Sulpiride--an antipsychotic agent: comparative trial vs. haloperidol.
    Cassano GB; Castrogiovanni P; Conti L; Bonollo L
    Psychopharmacol Bull; 1977 Jul; 13(3):41-3. PubMed ID: 18759
    [No Abstract]   [Full Text] [Related]  

  • 16. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine.
    Friedman J; Ault K; Powchik P
    Biol Psychiatry; 1997 Sep; 42(6):522-3. PubMed ID: 9285089
    [No Abstract]   [Full Text] [Related]  

  • 17. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
    Levinson I; Levine S
    Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessment of antipsychotic activity of an unique agent: SU-23397.
    Mielke EH; Gallant DM; Bishop G; Kessler CM
    Psychopharmacol Commun; 1975; 1(2):117-22. PubMed ID: 4858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of schizophrenia from the viewpoint of the patient. Studies on the course of treatment and neuroleptic treatment from a personal perspective].
    Windgassen K
    Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1989; 58():1-169. PubMed ID: 2576099
    [No Abstract]   [Full Text] [Related]  

  • 20. Do negative symptoms respond to pharmacological treatment?
    Kane JM; Mayerhoff D
    Br J Psychiatry Suppl; 1989 Nov; (7):115-8. PubMed ID: 2575914
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.